Human Trials

NeoTX enters into immuno-oncology clinical trial collaboration with AstraZeneca

NeoTX Therapeutics has entered into a clinical collaboration with AstraZeneca Group’s global biologics research and development arm, MedImmune to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox in combination with IMFINZI (durvalumab).

Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial

Moderna has announced the dosing of the first subject in a phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults.

Eisai, Purdue Pharma present efficacy and safety data from second phase 3 study of lemborexant

Eisai and Purdue Pharma announced six-month results from SUNRISE 2, a long-term Phase 3 clinical study evaluating the efficacy and safety of lemborexant, an investigational agent being developed for the treatment of insomnia, a sleep-wake disorder.

Verseon begins dosing in phase 1 trial of VE-1902 oral anticoagulant

Verseon has started dosing of its lead blood thinner candidate VE-1902 in a phase 1 trial held in healthy volunteers at Nucleus Network in Melbourne, Australia.

Eureka Therapeutics announces US FDA clearance of IND application for trial of ET140202 Artemis T-Cell therapy

Eureka Therapeutics, a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ET140202 ARTEMIS T-cell therapy in AFP-positive patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer.

Genentech halts two phase 3 AD trials of crenezumab over futility

Roche’s Genentech has decided to stop two phase 3 trials evaluating its anti-beta-amyloid molecule crenezumab in early Alzheimer’s disease (AD) for futility reasons.

Pfizer and Lilly’s tanezumab succeeds in second phase 3 osteoarthritis pain trial

Pfizer and Eli Lilly have announced positive top-line results from a phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.

Shield Therapeutics’ Feraccru yields positive results in extended phase 3 trial

Shield Therapeutics said that its oral ferric iron therapy Feraccru succeeded in the open-label extension phase of the AEGIS-CKD study held in chronic kidney disease (CKD) patients with iron deficiency anaemia (IDA).

Takeda’s TAK-003 dengue vaccine candidate succeeds in phase 3 efficacy trial

Takeda Pharmaceutical’s investigational live-attenuated tetravalent dengue vaccine (TAK-003) candidate has met the primary endpoint in the pivotal phase 3 efficacy trial.